Clinical Trial

Anlotinib Combined With Doxorubicin and Radiotherapy as Neoadjuvant Treatment for Soft Tissue Sarcoma

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
Exploring the Efficacy and Safety of Anlotinib Combined with Doxorubicin Monotherapy and Radiotherapy as Neoadjuvant Treatment for Soft Tissue Sarcoma
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-07-12.
Status change: Not Yet Recruiting → Recruiting 2024-08-08
Trial Details
NCT Number NCT06506838
Lead Sponsor Guangdong Provincial People's Hospital
Conditions Soft Tissue Sarcoma, Doxorubicin, Radiotherapy
Enrollment 39 participants
Start Date 2024-08-10
Primary Completion 2027-07-20 (estimated)
Study Completion 2028-07-20 (estimated)
Updated on ClinicalTrials.gov 2024-08-12